Open Orphan #ORPH – Notice of Interim Results, Analyst Briefing and Investor Presentation September 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its interim results for the six-month period ended 30 June 2021 will be released on Monday, 20 September 2021. Analyst Briefing A briefing open to analysts will take place remotely via video conference call on Monday 20 September at 9.30am (BST). If you would like the details…

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020. Operational Highlights: · Completed the acquisition of hVIVO…

Open Orphan #ORPH – Appointment of new Director February 27, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan , the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services , is pleased to announce, further to its announcement of 13 February 2020, the appointment to the board of Leo Toole as Chief Financial Officer. Leo Toole brings over 20 years’ experience in senior finance roles in Pharmaceuticals, Medical Technology and FMCG sectors. He…

Open Orphan #ORPH – Appointment of Group Chief Financial Officer February 13, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe’s only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London, is pleased to announce the appointment of Leo Toole to the role of Group Chief Financial Officer with immediate effect. Leo was previously Interim Chief Financial…

Open Orphan #ORPH – Notice of Interim Results, Analyst Briefing and Investor Presentation September 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – Appointment of new Director February 27, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – Appointment of Group Chief Financial Officer February 13, 2020 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL